Monoamine oxidase B inhibitor, selegiline, reduces 18 F-THK5351 uptake in the human brain

Alzheimers Res Ther. 2017 Mar 31;9(1):25. doi: 10.1186/s13195-017-0253-y.

Abstract

Background: 18F-THK5351 is a quinoline-derived tau imaging agent with high affinity to paired helical filaments (PHF). However, high levels of 18F-THK5351 retention in brain regions thought to contain negligible concentrations of PHF raise questions about the interpretation of the positron emission tomography (PET) signals, particularly given previously described interactions between quinolone derivatives and monoamine oxidase B (MAO-B). Here, we tested the effects of MAO-B inhibition on 18F-THK5351 brain uptake using PET and autoradiography.

Methods: Eight participants (five mild cognitive impairment, two Alzheimer's disease, and one progressive supranuclear palsy) had baseline 18F-AZD4694 and 18F-THK5351 scans in order to quantify brain amyloid and PHF load, respectively. A second 18F-THK5351 scan was conducted 1 week later, 1 h after a 10-mg oral dose of selegiline. Three out of eight patients also had a third 18F-THK5351 scan 9-28 days after the selegiline administration. The primary outcome measure was standardized uptake value (SUV), calculated using tissue radioactivity concentration from 50 to 70 min after 18F-THK5351 injection, normalizing for body weight and injected radioactivity. The SUV ratio (SUVR) was determined using the cerebellar cortex as the reference region. 18F-THK5351 competition autoradiography studies in postmortem tissue were conducted using 150 and 500 nM selegiline.

Results: At baseline, 18F-THK5351 SUVs were highest in the basal ganglia (0.64 ± 0.11) and thalamus (0.62 ± 0.14). In the post-selegiline scans, the regional SUVs were reduced on average by 36.7% to 51.8%, with the greatest reduction noted in the thalamus (51.8%) and basal ganglia (51.4%). MAO-B inhibition also reduced 18F-THK5351 SUVs in the cerebellar cortex (41.6%). The SUVs remained reduced in the three patients imaged at 9-28 days. Tissue autoradiography confirmed the effects of MAO-B inhibition on 18F-THK5351 uptake.

Conclusions: These results indicate that the interpretation of 18F-THK5351 PET images, with respect to tau, is confounded by the high MAO-B availability across the entire brain. In addition, the heterogeneous MAO-B availability across the cortex may limit the interpretation of 18F-THK5351 scans using reference region methods.

Keywords: 18F-THK5351 tau tracer; Alzheimer’s disease; Monoamine oxidase-B; Positron emission tomography; Selegiline.

MeSH terms

  • Aged
  • Alzheimer Disease / diagnostic imaging
  • Alzheimer Disease / metabolism
  • Aminopyridines / pharmacokinetics*
  • Autoradiography
  • Binding, Competitive
  • Brain / diagnostic imaging*
  • Brain / drug effects
  • Brain / metabolism
  • Cognitive Dysfunction / diagnostic imaging
  • Cognitive Dysfunction / metabolism
  • Drug Interactions
  • Female
  • Fluorine Radioisotopes / pharmacokinetics*
  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Middle Aged
  • Monoamine Oxidase / metabolism*
  • Monoamine Oxidase Inhibitors / pharmacology*
  • Positron-Emission Tomography
  • Quinolines / pharmacokinetics*
  • Radiopharmaceuticals
  • Selegiline / pharmacology*
  • Supranuclear Palsy, Progressive / diagnostic imaging
  • Supranuclear Palsy, Progressive / metabolism
  • tau Proteins / metabolism

Substances

  • Aminopyridines
  • Fluorine Radioisotopes
  • MAPT protein, human
  • Monoamine Oxidase Inhibitors
  • Quinolines
  • Radiopharmaceuticals
  • THK5351
  • tau Proteins
  • Selegiline
  • Monoamine Oxidase